A novel mannoside-glycocluster adjuvant: Compared in vitro to CpG ODN and MPL and tested in vivo in mouse asthma model - UTU Tutkimustietojärjestelmä

A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

A novel mannoside-glycocluster adjuvant: Compared in vitro to CpG ODN and MPL and tested in vivo in mouse asthma model

Tekijät: Makinen K, Mukherjee C, Leino M, Panchadhayee R, Lehto M, Wolff H, Alenius H, Leino R, Savolainen J

Kustantaja: ELSEVIER DOYMA SL

Julkaisuvuosi: 2016

Journal: Allergologia et Immunopathologia

Tietokannassa oleva lehden nimi: ALLERGOLOGIA ET IMMUNOPATHOLOGIA

Lehden akronyymi: ALLERGOL IMMUNOPATH

Vuosikerta: 44

Numero: 1

Aloitussivu: 9

Lopetussivu: 17

Sivujen määrä: 9

ISSN: 0301-0546

DOI: https://doi.org/10.1016/j.aller.2015.04.008

Tiivistelmä

Conclusions: TADM suppresses the birch allergen induced Th2-type cytokine responses in allergic subjects more efficiently than the two other adjuvants, MPL and CpG ODN. TADM is immunomodulatory also in vivo and decreases the IgE levels and increases the IFN-gamma responses in a murine model. These results suggest that TADM may be a promising candidate for novel adjuvants in immunotherapy. (C) 2014 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.